Open access peer-reviewed chapter - ONLINE FIRST

Pharmacological Treatment of Patent Ductus Arteriosus in Preterm Infants

Written By

Aimann Surak

Submitted: February 28th, 2022 Reviewed: March 9th, 2022 Published: April 11th, 2022

DOI: 10.5772/intechopen.104422

IntechOpen
Congenital Heart Defects - Recent Advances Edited by P. Syamasundar Rao

From the Edited Volume

Congenital Heart Defects - Recent Advances [Working Title]

Dr. Syamasundar Rao

Chapter metrics overview

12 Chapter Downloads

View Full Metrics

Abstract

The patent ductus arteriosus contribute to many neonatal morbidities. There are different approaches for treatment including conservative, pharmacological and definitive closure. Most commonly, pharmacological therapy is attempted before consideration of surgical intervention.

Keywords

  • preterm infant
  • PDA
  • NSAIDs

1. Introduction

Patent ductus arteriosus (PDA) was described a long time ago as a pathological entity in preterm babies [1]. From the physiological point of view, and outside the context of ductal-dependent lesions, PDA cannot be physiologically helpful when it comes to neonatal morbidity [2, 3].

In animal studies, there is significant engorgement and increased lymphatic conspicuity, secondary to dilated lymphatic architecture, in lambs with PDAs [4]. In primates, there is data suggesting that closing the PDA early makes a great difference in terms of the ventilation scores [4].

In humans, it takes only 3–7-day exposure to a moderate-large PDA shunt which significantly increases the incidence of bronchopulmonary dysplasia (BPD) [5] and BPD baseline incidence increases in preterm infants exposed to PDA [6].

PDA plays a critical role in the pathophysiology of many neonatal morbidities. This includes pulmonary hemorrhage [7, 8], myocardial changes in shape and size due to volume overload [9, 10], impaired bowel tissue oxygenation and other GI morbidities including necrotizing enterocolitis (NEC) [11, 12, 13, 14], increased incidence of renal injury [15], mortality and intraventricular hemorrhage (IVH) [14].

Different approaches exist and vary between centers. In this chapter, we will concentrate on the pharmacological approach.

Role of targeted neonatal echocardiography in detecting hemodynamically significant PDA:

There has not been a standardized consensus to define hemodynamically significant PDA [16, 17].

Clinical assessment on its own was found not sensitive or specific in predicting PDA shunt volume especially in the first few days of life [18]. In addition, ductal size (diameter) only does not define the significance of the ductal shunt. There are large size PDAs that have no hemodynamic significance, and the opposite is true as well.

It appears that a detailed echocardiographic assessment is the key using targeted neonatal echocardiography (TnEcho). This comprehensive assessment includes multiple domains (Figure 1). PDA characteristics are crucial to look at, which includes the diameter, PDA flow Doppler pattern as well as PDA shape. It is interesting to think about the morphology of the duct and how is it different in preterm as opposed to less preterm babies. Initially, 5 types of ducts were described from A to E, however, with the increasing number of preterm babies being referred for catheter closure, a 6th type was recognized. The F type (fetal type) ductus is exclusively found in children born prematurely and is long, wide, tortuous and unlikely to close with pharmacological treatments [19].

Figure 1.

Targeted neonatal parameters needed to establish the hemodynamic significance of PDA.

Assessment of pulmonary circulation is important to establish using multiple parameters (Figure 1). Due to poor compliance, assessment of myocardial adaptation to the high shunt load is crucial. In addition, the atrial shunt needs to be assessed and established. Finally, any evidence of systemic compromise should be elaborated as well.

Recently, few biochemical markers were suggested as a part of ductal assessment especially in resource-limited areas. This includes cardiac troponin T (TnT), atrial natriuretic peptide (ANP), brain-type natriuretic peptide (BNP), N-terminal pro-BNP (NTpBNP) and urinary neutrophil gelatinase-associated lipocalin and urinary heart-type fatty acid-binding protein [20, 21, 22, 23]. It appears that TnEcho is the proper tool to establish and define hemodynamically significant duct; only then treatment of PDA is shown to have an impact on neonatal outcomes [14, 17, 24, 25].

Advertisement

2. Pharmacological treatment of PDA in preterm infants

Pharmacological treatments induce ductal constriction with good effectiveness overall, whether using non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen in different routes of administration [25, 26, 27, 28, 29]. However, complete ductal closure or shunt elimination cannot be guaranteed even when combining these agents together; this is in addition to potential adverse side effects [30, 31, 32].

Advertisement

3. Non-steroidal anti-inflammatory drugs (NSAIDs)

It was known early on that NSAIDs induce ductal constriction and closure [25, 33, 34, 35]; this is even in infants who are born prematurely [36, 37]. Early treatment with indomethacin induces ductal closure, however, with concerns about compromising renal function [38]. This is probably due to the vasoconstrictive effects of those agents contributing to the development of renal hypoperfusion, NEC and spontaneous intestinal perforation (SIP), as well as platelet dysfunction and hyperbilirubinemia [39, 40].

A meta-analysis by Ohlsson et al. show that ibuprofen is equal to indomethacin in terms of efficacy in closing PDA with fewer side effects on the kidneys as well as reduced risk for NEC [41]. Rectal ibuprofen has been used as well with similar efficacy to oral ibuprofen [42]. It appears that indomethacin, the most widely used agent, is more prevalent in North America, and ibuprofen is more commonly used in Europe and Asia [43].

Repeated courses of NSAIDs are a common practice when initial treatment wasn’t completely successful in closing the PDA, keeping in mind, decreased efficacy with repeated courses [44, 45].

A higher dose of ibuprofen has been attempted as well, and this includes a loading dose of 20 mg/kg, followed by two subsequent doses of 10 mg/kg, 24 hours apart; this is in comparison to the standard dosing regimen which is a loading dose of 10 mg/kg, followed by two subsequent doses of 5 mg/kg, 24 hours apart. It appears that a higher dose of ibuprofen is more effective in closing the PDA, without an obvious increase in the side effects [41, 46].

3.1 Acetaminophen

Hammerman et al. reported the first case series of the use of acetaminophen as a therapeutic agent to facilitate ductal closure [27]. Acetaminophen inhibits the POX receptors on the prostaglandin synthesis pathway [29]. In a recent systematic review, Ohlsson et al. included 916 infants in eight studies comparing oral or intravenous acetaminophen to ibuprofen and found similar efficacy for acetaminophen with lower gastrointestinal bleeds, lower serum levels of creatinine, lower serum levels of bilirubin, and higher platelet count but no difference in the neurological outcomes between 18 and 24 months [28].

It is possible that acetaminophen may increase pulmonary vascular resistance [47].

3.2 Combination therapy

Another strategy that has been attempted, is combining acetaminophen with NSAIDs specifically ibuprofen which may provide a synergetic effect on the reduction of prostaglandin production, resulting in PDA closure. In a small randomized controlled trial (RCT), Hochwald et al. compared the combination of intravenous ibuprofen and intravenous acetaminophen versus intravenous ibuprofen alone. There was a trend towards increased efficacy with combination therapy but without a statistical difference (83% vs. 42%, p = 0.08); also, there was no increase in the side effects [30]. In an observational study by Yurttutan et al., combination therapy with oral ibuprofen and oral acetaminophen was successful in closing the ductus in 9 out of 12 infants who had failed two previous courses with no increase in the side effects [31]. A retrospective cohort by Kimani et al. did not demonstrate any increased adverse effects in the combination group [32].

3.3 Other strategies

Diuretics have been used as an adjunct agent to facilitate ductal closure. While diuretics help with symptomatic management of pulmonary over circulation, it appears that it compromises the systemic blood flow and may not provide a significant increase in the closure rates [48]. This is similar to a fluid restriction which may help managing the symptoms of chronic lung disease, but it would worsen the systemic blood flow [49, 50].

Advertisement

4. Conclusion

The PDA is common morbidity in preterm infants. There has been a trend towards more conservative management over surgical treatment [51]. The pharmacological treatment causes ductal constriction with good effectiveness overall whether using NSAIDs or acetaminophen in different routes of administration. However, complete ductal closure or shunt elimination cannot be guaranteed even when combining these agents together; this is in addition to potential adverse side effects.

Recently, FDA approved the use of Piccolo device for the purpose of PDA closure in preterm infants which was based of the efficacy and safety of such a device in this fragile population [2]. It appears that this catheter closure approach is becoming more popular as it is feasible, effective, and relatively safe [19, 52]. Whether this approach would result in more favorable neonatal morbidities and outcomes, needs further research.

Advertisement

Abbreviations

BPDBronchopulmonary dysplasia
NECNecrotizing enterocolitis
NSAIDsNon-steroidal anti-inflammatory drugs
PDAPatent ductus arteriosus
RCTRandomized controlled trial
SIPSpontaneous intestinal perforation
TnEcho

References

  1. 1. Powell ML. Patent ductus arteriosus in premature infants. The Medical journal of Australia. 1963;2:58-60
  2. 2. Vanhaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, van Hoestenberghe MR, Theyskens C. Conservative treatment for patent ductus arteriosus in the preterm. Archives of Disease in Childhood: Fetal and Neonatal Edition. 2007;92(4):244-247
  3. 3. Semberova J, Sirc J, Miletin J, Kucera J, Berka I, Sebkova S, et al. Spontaneous closure of patent ductus arteriosus in infants ≤1500 g. Pediatrics. 2017;140(2)
  4. 4. Alderliesten T, Lemmers PMA, Smarius JJM, van de Vosse RE, Baerts W, van Bel F. Cerebral oxygenation, extraction, and autoregulation in very preterm infants who develop peri-intraventricular hemorrhage. Journal of Pediatrics. 2013;162(4):698-704.e2
  5. 5. de Waal K, Kluckow M. Functional echocardiography; from physiology to treatment. Early Human Development. 2010;86(3):149-154. DOI: 10.1016/j.earlhumdev.2010.01.030
  6. 6. Datar SA, Johnson EG, Oishi PE, Johengen M, Tang E, Aramburo A, et al. Altered lymphatics in an ovine model of congenital heart disease with increased pulmonary blood flow. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2012;302(6):530-540
  7. 7. Chang LY, McCurnin D, Yoder B, Shaul PW, Clyman RI. Ductus arteriosus ligation and alveolar growth in preterm baboons with a patent ductus arteriosus. Pediatric Research. 2008;63(3):299-302
  8. 8. Clyman RI, Liebowitz M, Johng S, Clyman RI, Hills NK. Relationship between duration of infant exposure to a moderate-to-large patent ductus arteriosus shunt and the risk of developing bronchopulmonary dysplasia or death before 36 weeks. American Journal of Perinatology. 2020;37(2):216-223
  9. 9. Crump C, Groves A, Sundquist J, Sundquist K. Association of preterm birth with long-term risk of heart failure into adulthood. JAMA Pediatrics. 2021;175(7):689-697
  10. 10. Vaisbourd Y, Sharif D, Riskin A, Yaniv L, Dinur G, Amen K, et al. The effect of patent ductus arteriosus on coronary artery blood flow in premature infants: A prospective observational pilot study. Journal of Perinatology. 2020;40(9):1366-1374. DOI: 10.1038/s41372-020-0622-4
  11. 11. Lemmers PMA, Toet MC, van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics. 2008;121(1):142-147
  12. 12. Palder SB, Schwartz MZ, Tyson KRT, Marr CC. Association of closure of patent ductus arteriosus and development of necrotizing enterocolitis. Journal of Pediatric Surgery. 1988;23(5):422-423
  13. 13. McCurnin D, Clyman RI. Effects of a patent ductus arteriosus on postprandial mesenteric perfusion in premature baboons. Pediatrics. 2008;122(6):e1262-e1267
  14. 14. Sellmer A, Bjerre JV, Schmidt MR, McNamara PJ, Hjortdal VE, Høst B, et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Archives of Disease in Childhood: Fetal and Neonatal Edition. 2013;98(6):505-510
  15. 15. Chock VY, Rose LA, Mante J, v., Punn R. Near-infrared spectroscopy for detection of a significant patent ductus arteriosus. Pediatric Research. 2016;80(5):675-680
  16. 16. El-Khuffash A, James AT, David CJ, Dicker P, Franklin O, Elsayed YN, et al. A patent Ductus arteriosus severity score predicts chronic lung disease or death before discharge. The Journal of pediatrics. 2015;167(6):1354-1361.e2. DOI: 10.1016/j.jpeds.2015.09.028
  17. 17. Shepherd JL, Noori S. What is a hemodynamically significant PDA in preterm infants? Congenital Heart Disease. 2019;14(1):21-26
  18. 18. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. Journal of Paediatrics and Child Health. 1994;30(5):406-411
  19. 19. Philip R, Rush Waller B, Agrawal V, Wright D, Arevalo A, Zurakowski D, et al. Morphologic characterization of the patent ductus arteriosus in the premature infant and the choice of transcatheter occlusion device. Catheterization and Cardiovascular Interventions. 2016;87(2):310-317
  20. 20. Kluckow M, Evans N. Low superior vena cava flow and intraventricular haemorrhage in preterm infants. Archives of Disease in Childhood: Fetal and Neonatal Edition. 2000;82(3):F188-F194
  21. 21. EL-Khuffash A, Molloy E. The Use of N-Terminal-Pro-BNP in Preterm Infants. International Journal of Pediatrics. 2009;2009:1-7
  22. 22. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L’Ecuyer T. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. Journal of Perinatology. 2005;25(11):709-713
  23. 23. Byung MC, Kee HL, Baik LE, Kee HY, Young SH, Chang SS, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics. 2005;115(3):e255-e261
  24. 24. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: The need for disease staging. Archives of Disease in Childhood: Fetal and Neonatal Edition. 2007;92:F424-F427
  25. 25. Bussmann N, Smith A, Breatnach CR, McCallion N, Cleary B, Franklin O, et al. Patent ductus arteriosus shunt elimination results in a reduction in adverse outcomes: A post hoc analysis of the PDA RCT cohort. Journal of Perinatology. 2021;41(5):1134-1141
  26. 26. Starling MB, Elliott RB. The effects of prostaglandins, prostaglandin inhibitors, and oxygen on the closure of the ductus arteriosus, pulmonary arteries and umbilical vessels in vitro. Prostaglandins. 1974;8(3):187-203
  27. 27. Terrin G, Conte F, Oncel MY, Scipione A, McNamara PJ, Simons S, et al. Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis. Archives of Disease in Childhood: Fetal and Neonatal Edition. Mar 2016;101(2):F127-F136
  28. 28. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: A surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011;128(6):e1618-e1621
  29. 29. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database of Systematic Reviews. 2018;4(4):CD010061
  30. 30. Jasani B, Weisz DE, McNamara PJ. Evidence-based use of acetaminophen for hemodynamically significant ductus arteriosus in preterm infants. Seminars in Perinatology. 2018;42(4):243-252
  31. 31. Hochwald O, Mainzer G, Borenstein-Levin L, Jubran H, Dinur G, Zucker M, et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: A double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology. 2018;35(13):1319-1325
  32. 32. Yurttutan S, Bozkaya A, Hüdayioglu F, Oncel MY. The effect of combined therapy for treatment of monotherapy-resistant PDA in preterm infants. Journal of Maternal-Fetal and Neonatal Medicine. 2019;32(21):3662-3665
  33. 33. Kimani S, Surak A, Miller M, Bhattacharya S. Use of combination therapy with acetaminophen and ibuprofen for closure of the patent ductus arteriosus in preterm neonates. Paediatrics & Child Health. 2020;26(4):e177-e183
  34. 34. Elliott RB, Starling MB, Neutze JM. Medical manipulation of the ductus arteriosus. The Lancet. 1975;305(7899):140-142
  35. 35. Sharpe GL, Thalme B, Larsson KS. Studies on closure of the ductus arteriosus. XI. Ductal closure in utero by a prostaglandin synthetase inhibitor. Prostaglandins. 1974;8(5):585-596
  36. 36. Coceani F, Olley PM, Bodach E. Lamb ductus arteriosus: Effect of prostaglandin synthesis inhibitors on the muscle tone and the response to prostaglandin E2. Prostaglandins. 1975;9(2):299-308
  37. 37. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. New England Journal of Medicine. 1976;295(10):530-533
  38. 38. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. Obstetrical and Gynecological Survey. 1977;32(2):123-138
  39. 39. van Overmeire B, van de Broek H, van Laer P, Weyler J, Vanhaesebrouck P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics. 2001;138(2):205-211
  40. 40. Betkerur MV, Yeh TF, Miller K, Glasser RJ, Pildes RS. Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics. 1981;68(1):99-102
  41. 41. Kang NS, Yoo KH, Cheon H, Choi BM, Hong YS, Lee JW, et al. Indomethacin treatment decreases renal blood flow velocity in human neonates. Biology of the Neonate. 1999;76(5):261-265
  42. 42. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews. 2020;2020, 2(2):CD003481
  43. 43. Demir N, Peker E, Ece İ, Balahoroğlu R, Tuncer O. Efficacy and safety of rectal ibuprofen for patent ductus arteriosus closure in very low birth weight preterm infants. Journal of Maternal-Fetal and Neonatal Medicine. 2017;30(17):2119-2125
  44. 44. Irmesi R, Marcialis MA, Anker JVD, Fanos V. Non-steroidal anti-inflammatory drugs (NSAIDs) in the Management of Patent Ductus Arteriosus (PDA) in Preterm Infants and Variations in Attitude in Clinical Practice: A Flight Around the World. Current Medicinal Chemistry. 2014;21(27):3132-3152
  45. 45. Olgun H, Ceviz N, Kartal İ, Caner İ, Karacan M, Taştekin A, et al. Repeated courses of oral ibuprofen in premature infants with patent ductus arteriosus: Efficacy and safety. Pediatrics and Neonatology. 2017;58(1):29-35
  46. 46. Sangem M, Asthana S, Amin S. Multiple courses of indomethacin and neonatal outcomes in premature infants. Pediatric Cardiology. 2008;29(5):878-884
  47. 47. Dani C, Vangi V, Bertini G, Pratesi S, Lori I, Favelli F, et al. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: A randomized controlled study. Clinical Pharmacology and Therapeutics. 2012;91(4):590-596
  48. 48. Tamir Hostovsky L, Pan J, McNamara PJ, Belik J. Acetaminophen increases pulmonary and systemic vasomotor tone in the newborn rat. Pediatric Research. 2019;87:1171-1176. DOI: 10.1038/s41390-019-0725-9
  49. 49. Lee BS, Byun SY, Chung ML, Chang JY, Kim HY, Kim EAR, et al. Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period. Neonatology. 2010;98(2):191-199
  50. 50. de Buyst J, Rakza T, Pennaforte T, Johansson AB, Storme L. Hemodynamic effects of fluid restriction in preterm infants with significant patent ductus arteriosus. Journal of Pediatrics. 2012;161(3):404-408
  51. 51. Bell E, Acarregui M. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. The Cochrane Database of Systematic Reviews. 2001;2001
  52. 52. Sathanandam S, Balduf K, Chilakala S, Washington K, Allen K, Knott-Craig C, et al. Role of Transcatheter patent ductus arteriosus closure in extremely low birth weight infants. Catheterization and Cardiovascular Interventions. 2019;93(1):89-96

Written By

Aimann Surak

Submitted: February 28th, 2022 Reviewed: March 9th, 2022 Published: April 11th, 2022